Related references
Note: Only part of the references are listed.2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score Results From the FOURIER Trial
Nicholas A. Marston et al.
CIRCULATION (2020)
Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial
Amy Damask et al.
CIRCULATION (2020)
The complex molecular genetics of familial hypercholesterolaemia
Amanda J. Berberich et al.
NATURE REVIEWS CARDIOLOGY (2019)
Functional analysis of new variants at the low-density lipoprotein receptor associated with familial hypercholesterolemia
Carmen Rodriguez-Jimenez et al.
HUMAN MUTATION (2019)
Effect of Lipoprotein(a) on the Diagnosis of Familial Hypercholesterolemia: Does It Make a Difference in the Clinic?
Dick C. Chan et al.
CLINICAL CHEMISTRY (2019)
Risk of Premature Atherosclerotic Disease in Patients With Monogenic Versus Polygenic Familial Hypercholesterolemia
Mark Trinder et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Quantifying the polygenic contribution to variable expressivity in eleven rare genetic disorders
M. T. Oetjens et al.
NATURE COMMUNICATIONS (2019)
PCSK9 inhibition 2018: riding a new wave of coronary prevention
Natalie C. Ward et al.
CLINICAL SCIENCE (2019)
Lysosomal acid lipase deficiency - early diagnosis is the key
Georg Strebinger et al.
HEPATIC MEDICINE-EVIDENCE AND RESEARCH (2019)
Barriers and Facilitators to Genetic Testing for Familial Hypercholesterolemia in the United States: A Review
Rachele M. Hendricks-Sturrup et al.
JOURNAL OF PERSONALIZED MEDICINE (2019)
Understanding Implementation Challenges to Genetic Testing for Familial Hypercholesterolemia in the United States
Rachele M. Hendricks-Sturrup et al.
JOURNAL OF PERSONALIZED MEDICINE (2019)
The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland
Aleksandra Pelczarska et al.
ATHEROSCLEROSIS (2018)
The Present and the Future of Genetic Testing in Familial Hypercholesterolemia: Opportunities and Caveats
Amanda J. Hooper et al.
CURRENT ATHEROSCLEROSIS REPORTS (2018)
Validation of LDLr Activity as a Tool to Improve Genetic Diagnosis of Familial Hypercholesterolemia: A Retrospective on Functional Characterization of LDLr Variants
Asier Benito-Vicente et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
A Comparative Analysis of Phenotypic Predictors of Mutations in Familial Hypercholesterolemia
Dick C. Chan et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
The association between hypercholesterotemia and sitosterolemia, and report of a sitosterolemia kindred
Eliot A. Brinton et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2018)
Autosomal Recessive Hypercholesterolemia Long-Term Cardiovascular Outcomes
Laura D'Erasmo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry
Liam R. Brunham et al.
ATHEROSCLEROSIS (2018)
Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH)
Christos V. Rizos et al.
ATHEROSCLEROSIS (2018)
Clinical Genetic Testing for Familial Hypercholesterolemia
Amy C. Sturm et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Genomic Risk Prediction of Coronary Artery Disease in 480,000 Adults Implications for Primary Prevention
Michael Inouye et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
G. G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease
Michael M. Page et al.
DIABETES OBESITY & METABOLISM (2018)
Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism
Gerald F. Watts et al.
CIRCULATION (2017)
Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK
Marion Kerr et al.
EUROPEAN HEART JOURNAL (2017)
Recent advances in genetic testing for familial hypercholesterolemia
Michael A. Iacocca et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2017)
Sitosterolemia: A multifaceted metabolic disorder with important clinical consequences
Eleftheria Tzavella et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2017)
Polygenic risk score predicts prevalence of cardiovascular disease in patients with familial hypercholesterolemia
Martine Paquette et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2017)
Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association
Carl E. Orringer et al.
Journal of Clinical Lipidology (2017)
ABCG5/G8 gene is associated with hypercholesterolemias without mutation in candidate genes and noncholesterol sterols
Itziar Lamiquiz-Moneo et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2017)
Knowns and unknowns in the care of pediatric familial hypercholesterolemia
Andrew C. Martin et al.
JOURNAL OF LIPID RESEARCH (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia
Daniel Gaudet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
Mark J. Graham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Familial dysbetalipoproteinemia: an underdiagnosed lipid disorder
Charlotte Koopal et al.
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY (2017)
Identification and in vitro characterization of two new PCSK9 Gain of Function variants found in patients with Familial Hypercholesterolemia
Maria Donata Di Taranto et al.
SCIENTIFIC REPORTS (2017)
Interpreting the Mechanism of APOE (p.Leu167del) Mutation in the Incidence of Familial Hypercholesterolemia; An In-silico Approach
Omran Mohammed Rashidi et al.
OPEN CARDIOVASCULAR MEDICINE JOURNAL (2017)
Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH™ patient registry
Stephen M. Amrock et al.
ATHEROSCLEROSIS (2017)
Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN)
Maurizio Averna et al.
ATHEROSCLEROSIS SUPPLEMENTS (2017)
Predicting Cardiovascular Events in Familial Hypercholesterolemia The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study)
Leopoldo Perez de Isla et al.
CIRCULATION (2017)
Screening for familial hypercholesterolaemia in childhood: Avon Longitudinal Study of Parents and Children (ALSPAC)
Marta Futema et al.
ATHEROSCLEROSIS (2017)
Low-density lipoprotein receptor mutational analysis in diagnosis of familial hypercholesterolemia
Mafalda Bourbon et al.
CURRENT OPINION IN LIPIDOLOGY (2017)
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE
Paul S. Jellinger et al.
ENDOCRINE PRACTICE (2017)
Risk prediction by genetic risk scores for coronary heart disease is independent of self-reported family history
Hayato Tada et al.
EUROPEAN HEART JOURNAL (2016)
Genomic prediction of coronary heart disease
Gad Abraham et al.
EUROPEAN HEART JOURNAL (2016)
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis
Michael G. Silverman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Translational Research for Improving the Care of Familial Hypercholesterolemia: The Ten Countries Study and Beyond
Gerald F. Watts et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2016)
Familial defective apolipoprotein B-100: A review
Lars H. Andersen et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2016)
Thematic Review Series: Lipoprotein (a): Coming of Age at Last Structure, function, and genetics of lipoprotein (a)
Konrad Schmidt et al.
JOURNAL OF LIPID RESEARCH (2016)
Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia 5-Year SAFEHEART Registry Follow-Up
Leopoldo Perez de Isla et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia
Amit V. Khera et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Child-Parent Familial Hypercholesterolemia Screening in Primary Care
David S. Wald et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Interpretative comments specifically suggesting specialist referral increase the detection of familial hypercholesterolaemia
Robert Bender et al.
PATHOLOGY (2016)
Genetic identification of familial hypercholesterolemia within a single US health care system
Noura S. Abul-Husn et al.
SCIENCE (2016)
High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study
Anne Langsted et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
The importance of an integrated analysis of clinical, molecular, and functional data for the genetic diagnosis of familial hypercholesterolemia
Asier Benito-Vicente et al.
GENETICS IN MEDICINE (2015)
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
Sue Richards et al.
GENETICS IN MEDICINE (2015)
Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States
Christina X. Chen et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2015)
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2015)
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2015)
Refinement of Variant Selection for the LDL Cholesterol Genetic Risk Score in the Diagnosis of the Polygenic Form of Clinical Familial Hypercholesterolemia and Replication in Samples from 6 Countries
Marta Futema et al.
CLINICAL CHEMISTRY (2015)
Detecting familial hypercholesterolaemia in the community: Impact of a telephone call from a chemical pathologist to the requesting general practitioner
Damon A. Bell et al.
ATHEROSCLEROSIS (2014)
Mutations in STAP1 Are Associated With Autosomal Dominant Hypercholesterolemia
Sigrid W. Fouchier et al.
CIRCULATION RESEARCH (2014)
Novel functional APOB mutations outside LDL-binding region causing familial hypercholesterolaemia
Ana Catarina Alves et al.
HUMAN MOLECULAR GENETICS (2014)
Liver transplantation for the treatment of homozygous familial hypercholesterolaemia in an era of emerging lipid-lowering therapies
M. M. Page et al.
INTERNAL MEDICINE JOURNAL (2014)
Cascade screening based on genetic testing is cost-effective: Evidence for the implementation of models of care for familial hypercholesterolemia
Zanfina Ademi et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2014)
Advantages and Versatility of Fluorescence-Based Methodology to Characterize the Functionality of LDLR and Class Mutation Assignment
Aitor Etxebarria et al.
PLOS ONE (2014)
APOE p.Leu167del mutation in familial hypercholesterolemia
Zuhier Awan et al.
ATHEROSCLEROSIS (2013)
The Role of Early LDL Lowering to Prevent the Onset of Atherosclerotic Disease
Brian A. Ference et al.
CURRENT ATHEROSCLEROSIS REPORTS (2013)
Description of a Large Family with Autosomal Dominant Hypercholesterolemia Associated with the APOE p.Leu167del Mutation
Marie Marduel et al.
HUMAN MUTATION (2013)
A systematic review of economic evaluations of the detection and treatment of familial hypercholesterolemia
Zanfina Ademi et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
The extended abnormalities in lipoprotein metabolism in familial hypercholesterolemia: Developing a new framework for future therapies
Esther M. M. Ooi et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis
Ilenia Minicocci et al.
JOURNAL OF LIPID RESEARCH (2013)
Familial Hypercholesterolemia in the Danish General Population: Prevalence, Coronary Artery Disease, and Cholesterol-Lowering Medication
Marianne Benn et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Angiopoietin-like Protein 3 Inhibits Lipoprotein Lipase Activity through Enhancing Its Cleavage by Proprotein Convertases
Jun Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
C. Baigent et al.
LANCET (2010)
The Molecular Basis of Familial Hypercholesterolemia in Lebanon: Spectrum of LDLR Mutations and Role of PCSK9 as a Modifier Gene
Marianne Abifadel et al.
HUMAN MUTATION (2009)
Self-association of human PCSK9 correlates with its LDLR-degrading activity
Daping Fan et al.
BIOCHEMISTRY (2008)
Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation
Da-Wei Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Unravelling the functional significance of PCSK9
Gilles Lambert
CURRENT OPINION IN LIPIDOLOGY (2007)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease
S Tsimikas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Mutation in apolipoprotein B associated with hypobetalipoproteinemia despite decreased binding to the low density lipoprotein receptor
M Benn et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9
C Jonathan et al.
NATURE GENETICS (2005)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
Share Paper
